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Abstract
Background: The goal of tuberculosis elimination put forward in the End TB Strategy prioritizes diagnosis
and treatment of incipient and subclinical TB, recently defined by key stakeholders as “asymptomatic, early
pre-clinical disease during which pathology evolves”. Regarded as indicative of a high risk of TB progression,
considerable efforts have been made to identify these cases through exploration of biomarkers. The present
study aimed to evaluate simple scoring systems for TB exposure as screening tools for subclinical TB, the
only identifiable of the incipient and subclinical disease states, in a contact investigation (CI) setting of low
HIV-prevalence.
Methods: Nested within a large prospective study in household contacts (HHCs) of smear positive pulmonary TB
cases in South-India conducted 2010–2012, we assessed 1) the association between the Tuberculosis Contact Score
(TCS) and the Infectivity Score, with established tools for Mycobacterium tuberculosis (Mtb) infection, corrected for
established TB risk factors, and 2) the capability of the TB exposure scores to identify subclinical TB defined by Mtb-
culture positivity in sputum or gastric aspirate (subjects < 5 years) specimen.
Results: Of 525 HHCs, 29 were Mtb-culture positive and 96.6% of these asymptomatic. The TCS and the
Infectivity Score associated with positive Tuberculin Skin Test and QuantiFeron TB-Gold In-tube assay (QFT)
results in multivariate analyses (TCS: ORTST 1.16, 95% CI: 1.01, 1.33; ORQFT 1.33 95% CI: 1.16, 1.51. Infectivity
Score: ORTST 1.39, 95% CI: 1.10, 1.76; ORQFT 1.41 95% CI: 1.16, 1.71). The Infectivity Score showed a moderate
capability to identify subclinical TB (AUC of 0.61, 95% CI: 0.52, 0.70).
Conclusions: Although our results did not identify an easily applicable screening tool for subclinical TB, the
present study indicates that focusing on TB-related symptoms in CI settings may be of limited value for early
identification of HHCs with high risk for TB progression.
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Background
Globally, tuberculosis (TB) caused by Mycobacterium tu-
berculosis (Mtb) is the largest killer among infectious
diseases, causing an estimated 1.2 million deaths in 2018
[1]. Despite declining TB incidence achieved through
considerable joint efforts since the Stop TB Initiative [2],
the TB epidemic will represent a great challenge for
years to come: the estimated number of new TB cases
was 10.0 million in 2018 [1]. Traditionally, treatment of
cases has been the cornerstone of epidemiological con-
trol [2, 3]. In most high-endemic countries, case detec-
tion relies on patients seeking health-care because of
symptoms, but this strategy leaves 40% of estimated TB
cases undiagnosed [4]. In order to reduce the TB preva-
lence further, The End TB Strategy included in the Sus-
tainable developmental goals, emphasizes early diagnosis
of cases [5] including incipient TB defined as “asymp-
tomatic, early pre-clinical disease during which pathology
evolves, such as mycobacterial replication or the inflam-
matory response. Radiological abnormalities or positive
microbiological tests may or may not be present. This
state may either evolve and lead to symptomatic clinical
TB or regress and remain asymptomatic” [6]. Meeting
this ambitious goal will require systematic screening of
contacts and high risk groups for TB disease and subse-
quent preventive or full-length TB treatment where ad-
equate [5].
Being recently exposed, Mtb-infected household contacts
(HHCs) have increased risk of TB progression and are
therefore defined a target population for active case-finding
as part of contact investigations (CIs) [7]. The World
Health Organization (WHO) strongly recommends CIs by
health staff visiting households following diagnosis of all
smear positive pulmonary TB cases. In low-middle income
countries (LMICs) with TB incidence ≥100 per 100,000
population, CIs include evaluation for active TB in persons
of all ages with symptoms. If active TB is excluded, prevent-
ive treatment should be given to children aged < 5 years
and persons living with HIV (PLHIV) [8]. Although sug-
gested as a possible strategy to eliminate TB [9–11], giving
preventive treatment to all Mtb-infected subjects is not
practical in LMICs with moderate-high TB incidence as
health systems are already overwhelmed. Although the Tu-
berculin Skin Test (TST) and/or interferon-gamma release
assays (IGRAs) give evidence of Mtb-infection, these tests
have poor predictive value for future TB [12, 13] reducing
their relevance in the identification of incipient and subclin-
ical TB [14]. These disease states represent early TB disease
with high risk of TB progression and are likely to contribute
to continued transmission [6, 14]. Therefore, the World
Health Organization (WHO) and other stakeholders are
strongly encouraging and facilitating the development of
novel tests capable of identifying incipient and subclinical
TB [6, 15]. CI represents a reasonable well-established
framework for identification of these TB cases which would
have a large impact on the TB epidemic [9, 16] subse-
quently increasing national incentives to adhere to pro-
grammatic CIs [8]. Although the scientific community are
making progress in identifying host biomarker-based risk
signatures for TB progression [17–19], validation and ap-
proval according to defined target product profiles [6, 15]
will still take time.
Notably, risk factors for incipient/subclinical and active TB
can be assumed to be similar [14, 20–22]. The risk of Mtb-
infection and disease progression is generally accepted to be
strongly affected by the degree of exposure [23, 24]. There-
fore, a scoring system has been developed to quantify TB-
exposure in HHCs when evaluating the performance of the
TST and IGRAs in pediatric and adult populations [24–27].
The Tuberculosis Contact Score (TCS) contains multiple
subscores (Infectivity Score, Duration of Contact Score, Type
of Exposure Score and Duration of Symptoms Score) and, as
opposed to TST and IGRAs, does not require repeated visits
and laboratory facilities. Sputum smear grade alone has also
been found to associate with TST [28, 29] and QFT positivity
[30, 31]. We therefore hypothesized that TB-exposure scores
could serve as screening tools for incipient/subclinical TB.
Verification of incipient TB according to the recent consen-
sus definition by Kik et al., is indeed challenging [6]. Inspired
by Drain et al. who denotes subclinical TB as a categorical
state between incipient and clinical TB where cases can be
identified by microbiological or radiological evidence [14], we
considered laboratory confirmation a more robust evidence
of ongoing Mtb-replication than chest X-ray changes. We
therefore defined subclinical TB by growth ofMtb in respira-
tory (or gastric aspirate for children aged > 5 years) speci-
mens from recently exposed HHCs and argue that we
hereby identify the subjects with the highest bacterial burden
suggestive of risk of transmission and progression to overt
disease. Patient-reported symptoms are highly variable in
previous Asian studies even in definite TB cases [32], and
were therefore not included in our definition.
Thus, in the context of a prospective study of HHCs
of adult pulmonary TB index cases in South India, our
primary aim was to evaluate the potential of the TB ex-
posure scores TCS and the Infectivity Score (a TCS sub-
score), as screening tools for subclinical TB. We first
assessed the association between the TB exposure scores
for identifying Mtb-infection (TST and Quantiferon) and
subclinical TB while correcting for established TB risk
factors. We then evaluated the capability of the TB ex-
posure scores to identify individual contacts and/or fam-
ilies with ≥1 subclinical TB case.
Methods
Study population
The present study was a cross-sectional study nested
within a large prospective household contact (HHC)
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study conducted in Palamaner Taluk, Andhra Pradesh,
India (3.200°N, 72.7500°E, altitude 683 m) in the
period 2010–2012. The bacillus Calmette-Guérin vac-
cine (BCG) coverage in the area was > 90% in all pop-
ulations < 2 years except for the muslim minority
(81.4%) [33]. The HIV prevalence in tested pregnant
women in the area was 1–2% [34]. Index cases were
recruited through the RNTCP (Revised National TB
Control Program) when diagnosed with smear positive
pulmonary TB (PTB). Both index cases and household
contacts were enrolled in the HHC study: eligible
PTB cases were smear positive subjects aged > 18
years. Eligible contacts were persons living ≥75% of
the time in the same household as the index case and
sharing the same kitchen [35]. Contacts with previous
PTB or already on TB treatment/prophylaxis were ex-
cluded. Written informed consent was given by all
adults. Children aged 7–18 years gave their assents
followed by parental consent whereas parental con-
sent alone was given for children aged < 7 years.
Tuberculosis contact investigation
According to the study protocol, all participating con-
tacts were offered a comprehensive evaluation at base-
line. This included an interview on socioeconomic
conditions, medical history, TB-symptoms and clinical
examinations including weight, TST, the QuantiFeron
TB-Gold In-tube assay (QFT), two sputa (gastric aspi-
rates for children ≤5 years) harvested on two consecutive
days, for smear and culture, and chest X-rays (anterior
view for all, lateral view added on selected children < 5
years). First, a blood sample was drawn for the QFT that
was interpreted according to the manufacturer’s instruc-
tions (a positive test was defined as ≥0.35 IU/ml). Then
trained staff performed a TST by injecting 2 TU Purified
Protein Derivate (PPD, SPAN Diagnostics Ltd., Surat,
India) intra-dermally on the volar part of the left arm.
The following induration was read after 48-96 h (~ 80%
evaluated within 72 h, the remaining within 96 h) and
defined positive if ≥10mm. The TST was repeated after
1–4 weeks in HHCs with an induration < 5mm (n = 54),
and the baseline TST result defined as the larger of the
two tests. The chest X-rays were interpreted as either
“normal”, “abnormal, not TB” or “abnormal TB”, first by
a medical officer in the field, later by a radiologist whose
interpretation was preferred if discrepancy. Sputum/gas-
tric samples were evaluated by smear microscopy for
acid-fast bacilli (AFB) and cultured on both liquid (BAC-
TEC MGIT 960™ [Becton and Dickinson, USA]) and
solid (Lowenstein-Jensen) media. Identification of Mtb
was done using the GenoType MTBC test kit (HAIN
kit). All HHC participants were offered HIV-testing and
pre-test counselling at baseline.
TB exposure scores: the tuberculosis contact score and
the infectivity score
The Tuberculosis Contact Score (TCS) was based on
previously published scores when assessing children [24]
and adults [26], and modified to include HHCs of all
ages. Relationship score was excluded as data were
judged unreliable (Table 1).
The TCS was based on interview (three questions) and
sputum evaluation of the index cases assuming the gra-
dient of exposure to be a composite function of: 1) the
infectivity of the index case represented by the sputum
smear grade, graded 0–6 (Infectivity Score), 2) closeness
to the index case during sleep, graded 0–4 (Type of Ex-
posure Score), 3) the time (hours per day) spent with the
index case, graded 0–4 (Duration of Contact Score), and
4) duration of the index case’s symptoms before first
visit to the doctor, graded 0–4 (Duration of Symptoms
Score). The TCS is a sum of all subscores (max score
18); the higher the score, the greater the exposure and
risk of Mtb-infection and disease.
Categorization and definition of household contacts
(HHCs) according to Mtb-infection status and subclinical
TB
For analysis, HHCs were categorized according to their
Mtb-infection status at baseline defined by 1) TST and
QFT results (both tests required: TST and QFT negative;
TST or QFT positive; TST and QFT positive) or 2) sub-
clinical TB defined by positive Mtb-culture in sputum or
gastric aspirate (subjects < 5 years) specimen. Although
being asymptomatic is the key in the suggested defin-
ition for subclinical TB, broad reports from similar CI
settings in Asia suggest that 40–79% of active TB cases
do not report symptoms [32] highlighting the disease
continuum and difficulty in drawing a strict line between
subclinical and active TB. After all, finding all these
cases must be the goal of CIs. In accordance with the
suggested subclinical TB definition [14] and the study
aim of finding a screening tool applicable in the field,
categorization of subclinical TB was done irrespective of
chest X-ray results.
Statistical analysis
Categorical variables were reported as percentages. Con-
tinuous variables were summarized by mean and stand-
ard deviation or median and interquartile range, as
appropriate. TST (mm) and QFT (IU/ml) results were
analyzed both as continuous variables and as categorical
variables dichotomized around their cut-offs (TST ≥10
mm) and (QFT ≥0.35 IU/ml). Distribution of clinical
characteristics between HHCs categorized according to
Mtb-infection status was assessed with Chi-square test
and one-way analysis of variance (ANOVA) (Tukey
“Honest Significant Difference” method for post-hoc
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comparisons), where appropriate. Associations between
the independent variables TCS and established risk fac-
tors for TB (age, gender, BCG-scar, diabetes, smoking,
indoor pollution, crowding) and the dependent variables
1) TST and QFT results, and 2) subclinical TB, were
evaluated by univariate logistic regression, and multivari-
ate logistic regression adjusted for previously listed risk
factors for TB. Since assessment of body weight is differ-
ent in subjects aged ≥15 years (Body Mass Index, BMI)
and < 15 years (Body Mass Index Z-score, BMIZ), BMI
and BMIZ were only entered in the models evaluating
this variable, which were then stratified for age. All other
listed TB risk factors were entered in the BMI/BMIZ
models. Similar models were fitted to the Infectivity
Score. Unadjusted, predictive capabilities of TCS, the In-
fectivity Score, TST, and QFT for the individual contacts
and/or families with ≥1 contact Mtb culture positive at
baseline, were assessed using receiver operating charac-
teristic (ROC) curves and area under curve (AUC). A
significance level of p < 0.05 was used. IBM SPSS Soft-
ware, version 25 and R Core Team, 2018.
Results
Characterization of the study population
A total of 525 household contacts (HHCs) were re-
cruited from 176 index cases in the study area account-
ing for 94.3% of all eligible households. Index cases
reported a median of 20 days (IQR: [15, 30] days) from
onset of symptoms to first doctor visit, and a median of
6 days (IQR: [3, 20] days) from doctor visit to diagnosis.
At inclusion, 93 index cases (57%) had started treatment.
In these subjects, the median time from diagnosis to ini-
tiation of treatment was 2 days (IQR: [2, 4] days), and a
median of 2 days of treatment was given at the time of
CI (IQR: [1, 2] days). Baseline investigations were com-
pleted in 490 (93%) HHCs, in a median of 4 days (IQR:
[3, 5] days) in the 436 (83%) HHCs with only one TST,
and a median of 17.5 days (IQR: [15.0, 19.25]) in the 54
(10%) HHC with repeated TST. Adequate specimen for
Mtb culture were harvested in 493 (93.9%) HHCs. Of
these, 488 (99%) (and all 38 children < 5 years) had two
samples harvested on two consecutive days.
Males accounted for 40.5% of the study cohort, and
63% of the study cohort were aged > 14 years. BCG scar
was recorded in 221 (51.5%). All the 312 (60.4%) HHCs
that agreed to HIV-testing were HIV negative. Houses
were small with a mean of 4.25 (St.dev 2.04) subjects per
room. Indoor pollution can be assumed high as 75%
used wood and agricultural residue for fuel. In addition,
118 (24.8%) were/had been smokers for ≥6 months. The
distribution of gender, age, TB risk factors and clinical
parameters within the Mtb-infection categories are given
in Table 2.
Among the 29 subclinical TB cases, one (5.5%) had
symptoms, one had a positive smear and “abnormal TB”
chest X-rays, one had “abnormal TB” and one “abnor-
mal, not TB” chest X-ray.
Association between TB exposure scores and Mtb-
infection in HHCs
Although the association between TCS and TST/QFT is
established in other cohorts [24–27], we first investi-
gated the strength of this association in the present In-
dian cohort corrected for established risk factors for TB.
The TCS and the Infectivity Score was associated with
positive TST and QFT both in univariate and in multi-
variate analysis (Table 3).
In the multivariate models, the likelihood for a positive
TST increased by 16% (95% CI: 1–33%) per unit increase
in the TCS and by 39% (95% CI: 10–76%) per unit
Table 1 The Tuberculosis (TB) Contact Score. Maximum score
per subject = 18
Tuberculosis Contact Score (TCS) Pre-assigned
weight
Infectivity of the index case1
No known TB contact 0
Unknown sputum smear status 1
Sputum acid-fast2 negative 2
Sputum acid-fast2 1+ 3
Sputum acid-fast2 2+ 4
Sputum acid-fast2 3+ 5
Sputum acid-fast2 4+ 6
Type of exposure to index case1
No known/unknown exposure 0
Index case lives and sleep in different house 1
Index case lives and sleep in same house 2
Index case lives and sleep in same room 3
Index case lives and sleep in same bed 4
Duration (total hours) of contact per average
day with index case1
No known/unknown duration of contact 0
0–3 h 1
4–7 h 2
8–11 h 3
≥ 12 h 4
Duration of TB symptoms in index case1
No symptoms or unknown duration of
symptoms
0
< 3 weeks 1
4–7 weeks 2
8–11 weeks 3
≥ 12 weeks 4
1Index case: Adult with confirmed pulmonary tuberculosis. 2Direct fluorescent
microscopy with Auramin staining
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Table 2 Distribution of age, gender and risk factors for tuberculosis (TB) in 525 household contacts of 176 adults with confirmed
pulmonary TB according to infection categories at baseline Contact Investigation
Missing Total with available data
N = 525
TST−/QFT-1 N =
167
TST+ or QFT + 1
N = 167
TST+/QFT + 1
N = 113
Subclinical TB2 at baseline
N = 29
n (%) n (%) n (%) n (%) n (%) n (%)
Interview
Gender (male) 49 (9.3) 193 (40.5) 79 (47.3) 61 (36.5) 39 (34.5) 14 (48.3)
Age (years)3 50 (9.5)
< 5 38 (8.0) 22 (13.2) 8 (4.8) 6 (5.4) 2 (6.9)
5–14 138 (29.1) 41 (24.6) 47 (28.1) 38 (33.9) 12 (41.4)
> 14 299 (62.9) 104 (62.3) 112 (67.1) 68 (60.7) 15 (51.7)
Individual risk factors
Diabetes mellitus 49 (9.3) 9 (1.9) 2 (1.2) 5 (3.0) 1 (0.9) 1 (3.4)
Smoking 49 (9.3) 118 (24.8) 35 (21.0) 48 (28.7) 27 (23.9) 8 (27.6)
Tuberculosis Contact Score
Mean (St.dev) 10.9 (2.3) 10.4 (2.3) 11.1 (2.3) 11.6 (2.0) 11.2 (1.8)
Symptoms4 13 (2.7) 5 (3.0) 4 (2.4) 3 (2.7) 1 (3.4)
Environmental risk factors
Crowding5 (mean, St.dev) 55
(10.5)
4.25 (2.04) 4.41 (2.25) 4.14 (1.98) 4.18 (1.89) 3.43 (1.53)
In-door pollution6 55
(10.5)
LPG 60 (11.4) 14 (9.8) 21 (14.2) 17 (16.3) 2 (7.4)
Kerosene 15 (2.9) 3 (2.1) 4 (2.7) 5 (4.8) 1 (3.7)
Wood + agri residue 329 (75.2) 126 (88.1) 123 (83.1) 82 (78.8) 24 (88.9)
Examination and tests
Tuberculin Skin Test (TST) 49 (9.3)
mm (median, range) 8.0 (34) 6.0 (9) 7.0 (34) 14.0 (23) 7.0 (12)
≥ 10 mm 152 (31.9) 0 30 (18.0) 113 (100) 9 (31.0)
Quantiferon (QFT) 51 (9.7)
IU/mL (median, range) 0.56 (19.8) 0.03 (3.2) 1.44 (10.7) 4.58 (9.6) 1.36 (10.1)
≥ 0.35 IU/mL 266 (56.1) 0 137 (82.0) 113 (100) 16 (59.3)
Mtb specimen for culture 32 (6.1)
2 of 2 samples harvested 471 (98.9) 162 (97.9) 167 (100) 113 (100) 29 (100)
1 of 2 samples harvested 5 (1.1) 5 (3.0) 0 0 0
Smear + 7 (1.5) 2 (1.2) 2 (1.2) 2 (1.8) 1 (3.4)
Chest X-ray 49 (9.3)
Abnormal, not TB 13 (2.7) 4 (2.4) 1 (0.6) 7 (6.2) 1 (3.4)
Abnormal, TB 15 (3.2) 3 (1.8) 7 (4.2) 3 (2.7) 2 (6.9)
BCG scar present 96
(18.3)
Yes 221 (51.5) 85 (55.6) 76 (50.7) 46 (46.0) 14 (53.8)
BMI and BMIZ7
BMI when aged ≥15 years. Mean
(st.dev)
29 (8.8) 19.6 (3.19) 19.30 (3.03) 20.15 (3.72) 19.25 (2.61) 18.69 (2.13)
BMIZ when aged< 15 years. Mean
(st.dev)
9 of
187
−0.14 (1.70) − 0.48 (1.85) 0.19 (1.33) −0.14 (1.91) − 0.15 (1.71)
1Tuberculin Skin Test (TST) was dichotomized around the cutoff 10 mm; ≥10mm corresponding to TST+ and < 10mm corresponding to TST-. Quantiferon
(QFT) was dichotomized around the cutoff 0.35 IU/mL; ≥0.35 IU/mL corresponding to QFT+ and < 0.35 IU/mL corresponding to QFT-. Analysis limited to
subjects with both test results. 2Subjects with growth of Mycobacterium tuberculosis (Mtb) in liquid culture of respiratory specimen. 3WHO based age
categories.4 ≥ 1 of the following: cough > 2 wks, fever/night sweats, loss of weight/appetite, haemoptysis, chestpain. 5Number of household members divided
on rooms in the house. 6By type of fuel: LPG, Kerosene, Wood + agricultural residue. 7Body Mass Index (BMI), Body Mass Index Z-score (BMIZ)
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increase in the Infectivity Score, whereas the likelihood
for a positive QFT increased 33% (95% CI: 16–51%) per
unit TCS and 41% (95% CI: 16–71%) per unit increase of
the Infectivity Score. Surprisingly, LPG fuel, indicative of
higher SES and less indoor pollution, was significantly asso-
ciated with a positive TST in multivariate analysis (TCS
model: OR 2.05, 95% CI: 1.07, 3.93. Infectivity Score model:
OR 1.96, 95% CI: 1.02, 3.76). Notably, the association was
not present when analyses were limited to HHCs ≥15 years
regardless of BMI being included in analyses. No other
known TB risk factors associated with TST or QFT result.
Association between TB exposure scores and subclinical
TB in HHCs
There was no association between the TCS or the Infect-
ivity Score and subclinical TB (Table 4).
Of TB risk factors, only crowding was associated with sub-
clinical TB (TCS multivariate model: OR 0.72, 95%CI: 0.54,
0.95. Infectivity Score multivariate model: OR 0.71, 95% CI:
0.53, 0.95). This negative association was unexpected as
crowding normally increases TB risk [36]. Notably, crowding
was not significant in the BMI model, suggesting interaction
between BMI and crowding. To explore this, the interaction
BMI/crowding was entered in the model resulting in no sig-
nificant association for crowding alone.
The capacity of TB exposure scores to identify subclinical
TB
Finally, we assessed the capability of the TB exposure
scores to identify individual contacts and/or families
with ≥1 contact with subclinical TB. For comparison,
the same analyses were performed for TST and QFT at
baseline CI. As our aim was to evaluate the potential of
the TB exposure scores as robust screening tools, no ad-
justments were made. The TCS and the established im-
munological tools, TST and QFT, all had AUC values
close to 0.5 indicating no capability to identify individual
HHCs and/or families with ≥1 HHC with Mtb-positive
Table 3 Associations between Tuberculosis Contact Score, the Infectivity Score and other risk factors for tuberculosis (TB) and the
dependant variables TST1 and QFT1 in 525 household contacts of 161 adults with pulmonary TB
TST- vs TST + 1 QFT- vs QFT + 1
univariate multivariate2 multivariate3 univariate multivariate2 multivariate3
OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI)
Tuberculosis Contact Score 1.15 (1.05, 1.26) 1.16 (1.01, 1.33) 1.22 (1.12, 1.32) 1.33 (1.16, 1.51)
InfectivityScore 1.28 (1.11, 1.48) 1.39 (1.10, 1.76) 1.25 (1.11, 1.42) 1.41 (1.16, 1.71)
Gender 1.44 (0.97, 2.13) 1.35 (0.85, 2.15) 1.37 (0.87, 2.18) 1.38 (0.95, 1.99) 1.38 (0.88, 2.16) 1.47 (0.94, 2.28)
Age (years)4
< 5 0.44 (0.19, 1.02) 0.71 (0.27, 1.87) 0.72 (0.28, 1.88) 0.46 (0.23, 0.91) 0.87 (0.36, 2.11) 0.81 (0.34, 1.92)
5–14 1.07 (0.70, 1.62) 1.05 (0.61, 1.82) 1.05 (0.61, 1.82) 1.20 (0.79, 1.81) 1.27 (0.74, 2.17) 1.32 (0.77, 2.24)
> 14 ref ref ref ref ref ref
BCG scar present 0.93 (0.62, 1.38) 1.04 (0.65, 1.65) 1.02 (0.64, 1.63) 0.66 (0.45, 0.97) 0.64 (0.40, 1.01) 0.63 (0.40, 1,00)
Individual risk factors
Diabetes mellitus 0.26 (0.03, 2.09) 0.22 (0.03, 1.83) 0.22 (0.03, 1.84) 2.80 (0.58, 13.61) 3.41 (0.62, 18.69) 3.26 (0.60, 17.79)
Smoking 1.21 (0.78, 1.86) 1.64 (0.93, 2.89) 1.67 (0.94, 2.96) 1.18 (0.77, 1,79) 1.15 (0.65, 2.04) 1.15 (0.65, 2.03)
≥ 1 individual risk factors 1.19 (0.77, 1.82) 1.21 (0.80, 1.84)
BMI5a 0.98 (0.90, 1.05) 0.96 (0.86, 1.06) 0.96 (0.88, 1.06) 1.03 (0.96, 1.11) 0.97 (0.88, 1.06) 0.99 (0.90, 1.08)
BMIZ5b 1.03 (0.86, 1.24) na na 1.16 (0.97, 1.38) na na
Environmental risk factors
Crowding6 1.01 (0.91, 1.11) 1.09 (0.97, 1.22) 1.09 (0.97, 1.22) 0.92 (0.84, 1.01) 0.99 (0.88, 1.11) 0.97 (0.87, 1.08)
In-door pollution7
LPG 1.78 (1.01, 3.15) 2.05 (1.07, 3.93) 1.96 (1.02, 3.76) 1.48 (0.81, 2.68) 1.28 (0.65, 2.54) 1.25 (0.63, 2.47)
Kerosene 1.89 (0.62, 5.76) 2.17 (0.67, 7.08) 2.34 (0.72, 7.59) 1.80 (0.55, 5.96) 1.15 (0.33, 4.09) 1.37 (0.39, 4.83)
Wood + agri residue ref ref ref ref ref ref
1Tuberculin Skin Test (TST) was dichotomized around the cutoff 10mm; ≥10 mm corresponding to TST+ and < 10mm corresponding to TST-. Quantiferon (QFT)
was dichotomized around the cutoff 0.35 IU/mL; ≥0.35 IU/mL corresponding to QFT+ and < 0.35 IU/mL corresponding to QFT- (Subjects with indeterminate QFT is
excluded from analysis). 2Analysis including the TCS; 3Analysis including the Infectivity Score. 4WHO based age categories. 5Since assessments of body weight is
different in 5asubjects aged ≥15 years (Body Mass Index, BMI) and 5b < 15 years (Body Mass Index Z-score, BMIZ), BMI and BMIZ were only entered in the models
evaluating this variable, which were then done stratified for age. 6Number of household members divided on rooms in the house. 7Grading based on type of fuel,
(Wood + agricultural residue) = 3, Kerosene = 2, LPG = 1
ORs in bold are significantly different from 1 (p<0.05)
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cultures (data not shown). Interestingly, the simpler In-
fectivity Score showed moderate capability to identify in-
dividual contacts (AUC of 0.61, 95% CI: 0.52, 0.70) but
marginal capability to identify families with ≥1 contact
with growth of Mtb-positive sputum cultures (AUC of
0.58, 95% CI: 0.48, 0.68) (Fig. 1).
Discussion
To our knowledge, the present study is the first to assess
the Tuberculosis Contact Score (TCS) and the Infectivity
Score as screening tools for subclinical TB in a CI set-
ting. Currently, no tools are available for this purpose.
Even with promising host biomarker-based risk signa-
tures for TB progression [17–19], validation in various
populations as well as translation to a point-of-care test
format, will take time [6, 15]. Therefore, the present
study was motivated by our hope that simple scoring
systems, previously proven to reflect TB exposure, a
well-established risk factor for TB, could fill some of this
gap. Being independent of laboratory and X-ray facilities,
the TCS or the Infectivity Score can easily be applied as
a screening tool resulting in more targeted CIs either by
sorting out low-risk families/subjects where no CI could
be justified, or identify high-risk families/subjects war-
ranting referral for further TB investigations. Regret-
tably, the TCS could not reliably identify individual
subjects or families with subclinical TB. The Infectivity
Score performed better with a significant capacity to
identify subjects and families with subclinical TB with
an AUC of 0.61 and 0.58 respectively. This is however,
not good enough for a screening test [37] to identify
low-risk (“rule-out”) or high-risk (“rule-in”) families/sub-
jects, underlining the need for continued search for host
biomarkers for this screening purpose. Nevertheless, the
present study adds an important aspect for CIs. Notably,
the strong recommendations for CI for active case find-
ing in all households of sputum positive TB index pa-
tients [8, 38] focus on symptomatic HHCs. The present
study, one of very few studies from India where sputum
samples for both smear and culture were collected from
Table 4 Associations between Tuberculosis Contact Score, the Infectivity Score and other risk factors for tuberculosis (TB) and the
dependent variables TST1 and QFT1 in 525 household contacts of 161 adults with pulmonary TB
Subclinical TB vs other HHCs
univariate multivariate2 multivariate3
OR (95% CI) OR (95% CI) OR (95% CI)
Tuberculosis Contact Score 1.07 (0.90, 1.27) 0.98 (0.76, 1.27)
InfectivityScore 1.31 (0.96, 1.80) 1.35 (0.87, 2.12)
Gender 0.71 (0.34, 1.52) 0.78 (0.32, 1.85) 0.75 (0.32, 1.81)
Age (years)4
< 5 1.05 (0.23, 4.80) 2.14 (0.37, 12.3) 2.39 (0.42, 13.7)
5–14 1.80 (0.82, 3.96) 2.63 (0.87, 7.96) 2.71 (0.88, 8.33)
> 14 ref ref ref
BCG scar present 1.11 (0.50, 2.45) 1.01 (0.41, 2.50) 0.99 (0.40, 2.44)
Individual risk factors
Diabetes mellitus 1.96 (0.24, 16.2) 1.53 (0.17, 14.0) 1.73 (0.19, 16.2)
Smoking 1.17 (0.50, 2.71) 1.61 (0.49, 5.27) 1.63 (0.49, 5.38)
≥ 1 individual risk factors 1.11 (0.48, 2.58)
BMI5 0.89 (0.73, 1.09) 0.92 (0.73, 1.16) 0.92 (0.73, 1.16)
BMIZ5 1.00 (0.73, 1.38) 0.87 (0.61, 1.24) 0.82 (0.56, 1.19)
Environmental risk factors
Crowding6 0.79 (0.62, 0.99) 0.72 (0.54, 0.95) 0.71 (0.53, 0.95)
In-door pollution7
LPG 0.53 (0.12, 2.31) 0.45 (0.10, 2.08) 0.38 (0.08, 1.78)
Kerosene 1.15 (0.14, 9.22) 0 0
Wood + agri residue ref ref ref
1Tuberculin Skin Test (TST) was dichotomized around the cutoff 10mm; ≥10 mm corresponding to TST+ and < 10mm corresponding to TST-. Quantiferon (QFT)
was dichotomized around the cutoff 0.35 IU/mL; ≥0.35 IU/mL corresponding to QFT+ and < 0.35 IU/mL corresponding to QFT- (Subjects with indeterminate QFT is
excluded from analysis). 2Analysis including the TCS. 3Analysis including the Infectivity Score. 4WHO based age categories. 5Since assessments of body weight is
different in 5asubjects aged ≥15 years (Body Mass Index, BMI) and 5b < 15 years (Body Mass Index Z-score, BMIZ), BMI and BMIZ were only entered in the models
evaluating this variable, which were then done stratified for age. 6Number of household members divided on rooms in the house
ORs in bold are significantly different from 1 (p<0.05)
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all HHCs regardless of signs and symptoms of disease,
provides clear evidence that the majority of HHCs with
replicating Mtb in respiratory specimen were asymptom-
atic. The discrepancy between symptoms, X-ray findings
and Mtb-culture results is remarkable, and illustrates the
challenge of early identification of cases based on
patient-reported symptoms. Among the 525 HHCs, 29
met our definition of subclinical TB (5.5%), but only 1 of
the Mtb-culture positive participants had symptoms
qualifying for a co-prevalent case (0.2%). Of 525 HHCs,
13 (2.7%) reported symptoms, but only one of the symp-
tomatic HHCs (8.3%) had Mtb-positive cultures. There-
fore, in a regular CI setting where microbiological
sampling is, at best, done only in symptomatic subjects
[5], 28 of 29 (96.6%) subclinical cases would remain un-
detected. The frequency of Mtb-culture positivity of
5.5% HHCs in the present study, is remarkably high
compared to the reported 0.23% of Mtb-culture positiv-
ity in symptomatic Indian patients (passive case-finding)
[39, 40], but comparable to another Indian Study (4.3%)
[41]. We do though, acknowledge that our definition of
subclinical TB that relied on Mtb-culture results only,
and not on chest X-ray findings as suggested by Drain
et al. [14], might have underestimated the number of
subclinical TB cases. Interestingly, only 2 (6.9%) had X-
ray changes suggestive of TB and none of these had
symptoms. The same picture was observed for HHCs
within the other Mtb-infection categories with X-ray
changes suggestive of TB: Of 3 TST−/QFT- subjects
none had symptoms, of 6 TST+ or QFT+ one had symp-
toms, and of 3 TST+/QFT+ none had symptoms. There-
fore, we argue that our Mtb-culture based definition of
subclinical TB is the most objective and robust tool for
identification of subjects with high-risk for progressive
disease and transmission [42–45]. We acknowledge
though, that the relevance of Mtb-replication and transi-
ent excretion in the early phase of Mtb-infection re-
ported in children [46], that probably also occurs in
adults, could be questioned, as successful containment
and spontaneous recovery can be expected in an un-
known proportion of subjects [14].
The window of HHC enrollment following TB index
case identification could influence the number of HHCs
with ongoing Mtb-replication verified by positive cultures.
The present study succeeded in rapid inclusion of HHCs
illustrated by 42.6% of TB index cases not yet on treat-
ment at inclusion. The delay to diagnosis for the index
cases was higher in our study (mean 20 days) than in other
Indian studies (mean 6–16 days) [47–49], but lower than
in LMICs other than Sub-Saharan Africa (median 27 days)
[50]. Furthermore, the majority of included HHCs had
baseline investigations efficiently completed within a me-
dian of 4 days (83%), and all completed within 40 days.
Of further relevance is the vulnerability for Mtb-infec-
tion and subclinical TB in our population for which the
presence of TB risk factors in the study population could
be indicative: Despite a high reported BCG-coverage
[33], only 51.1% of all HHCs in our study had a BCG
Fig. 1 The capability of the Infectivity Score to identify individual household contacts (HHCs) with growth of Mtb in sputum cultures (A) and
families with ≥1 HHCs (B)
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scar compared to > 80% in a semi-urban population in
Delhi [41]. Interestingly, scar rates of only 47.5% were
reported in newborns with low birthweight [51]. A pro-
spective cohort study conducted (2006–2008) in the
same study area reported a birthweight of ≤2500 g in
29% of 4382 neonates [52] which taken together suggests
an explanation for the low BCG scar rate in the present
study.
Surprisingly, and despite the fact that we for the first
time confirmed a clear association between the TB ex-
posure scores and TST/QFT in an Indian HHC popu-
lation, neither the TB exposure scores or other well-
established TB risk factors had a clear association with
subclinical TB in multivariate analysis. There are mul-
tiple possible explanations: Although high TB expos-
ure outside the household is the most evident, this
seems unlikely given the Indian TB incidence about
180 per 100,000 in the study period [4]. It may be pos-
sible that the moderate size of our study cohort means
that it is not entirely comparable with findings from
large epidemiological studies [21, 22, 36]. Further-
more, it is possible that the considerable crowding
(mean of 4.25 persons per room) have affected nega-
tively the performance of the TCS by causing less dif-
ferentiated exposure of the HHCs to the index case.
Crowding might also decrease the association ob-
served in large-scale studies between smoking and TB
disease due to passive smoking. The size of the house-
holds in the present study (median of 5) was similar to
another HHC study in rural Indian [53]. Semi-urban
and urban Indian families tend to be smaller [41, 54],
but congested living is common in both rural and
urban areas [41] with 96.8% of families in the present
study living in 1–2 rooms. Interestingly, multivariate
analyses revealed a possible interaction between BMI
and crowding that could confound the results. Not-
ably, children aged < 15 could not be included in
multivariate analyses assessing BMI as BMI is an in-
valid measurement in this age group. For HHCs aged
≥15 years, HHCs with and without subclinical TB had
a mean BMI of 18.7 (St.dev 2.13) and 19.6 (St.dev
3.25) respectively. This was considerably lower than
the BMI in two large Peruvian HHC Study cohorts
(mean BMI 25.2 and 25.6). Interestingly, the dose-
response log-linear relationship between BMI and TB
incidence reported in a meta-analysis, was less certain
at BMI < 18.5 and > 30 [21].
The strengths of the present study are inclusion of
HHCs of all ages, detailed sociodemographic data, a thor-
ough work-up of most contacts with TST, QFT, sputum
or gastric aspirate samples for both smear and cultures,
combined with data on the TCS and Infectivity Score for
all HHCs. A major weakness is the lack of 18–24months
follow-up data in accordance with current consensus
definition for incipient TB [6]. Another limitation is due
to the 18% missing data in the study. The missing data
may be the reason that some associations may not have
been detected. Moreover, as the missingness pattern is at
least partly attributable to missing not at random mecha-
nisms (e.g., different types of non-responders) there is a
risk of bias in the reported associations.
Conclusions
Although our results were disappointing with regard to
our hope of identifying an easily applicable screening
tool for subclinical TB, the present study provides rele-
vant information to CIs as framework for identification
and early treatment of subclinical TB required to achieve
the ambitious goal of the End TB Strategy [5]. Findings
in our cohort indicate that focusing on TB-related symp-
toms is of little value in identifying HHCs with replicat-
ing Mtb in respiratory specimens, as this strategy would
have left 96.6% of HHCs with Mtb-positive cultures un-
identified. Although other studies support more targeted
identification of subjects with high TB risk based on
other TB risk assessment-based framework [21, 22, 36],
it is questionable whether exploring and validating even-
tual new TB risk scores offers a viable alternative to host
biomarker-based screening tools for subclinical TB,
which are strongly needed to reach the ambitious goal of
TB elimination.
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